专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06727257B1 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines 失效
标题翻译： 5-（杂环烷基）-6-芳基 - 二氢嘧啶
公开(公告)号：US06727257B1
公开(公告)日：2004-04-27
申请号：US09730458
申请日：2000-12-05
申请人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski , Bharat Lagu , Shou Wu Miao
发明人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski , Bharat Lagu , Shou Wu Miao
IPC分类号： C07D40106
CPC分类号： C07D239/30 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/14 , C07D491/04
摘要： This invention is directed to dihydropyrimidine compounds of the following formula: wherein A is which are selective antagonists for human &agr;1C receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where antagonism of the &agr;1C receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及下式的二氢嘧啶化合物：其中A是人α1C受体的选择性拮抗剂。本发明还涉及这些化合物用于降低眼内压，抑制胆固醇合成，放松下尿路组织，治疗良性前列腺增生，阳ence，心律失常以及用于治疗任何α1C受体拮抗作用的疾病有用本发明还提供了包含治疗有效量的上述化合物和药学上可接受的载体的药物组合物。

2. 发明授权

US5942517A 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines 失效
标题翻译： 5-（杂环烷基）-6-芳基 - 二氢嘧啶
公开(公告)号：US5942517A
公开(公告)日：1999-08-24
申请号：US978682
申请日：1997-11-26
申请人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski
发明人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski
IPC分类号： C07D239/22 , A61K20060101 , A61K31/505 , A61K31/506 , A61P3/06 , A61P9/06 , A61P13/02 , A61P13/08 , A61P15/00 , A61P25/04 , A61P43/00 , C07D20060101 , C07D239/30 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/14 , C07D453/02 , C07D491/04 , C07D491/048 , C07D521/00 , C07D239/32
CPC分类号： C07D239/30 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/14 , C07D491/04
摘要： This invention is directed to dihydropyrimidine compounds which are selective antagonists for human .alpha..sub.1C receptors and which have the structure: ##STR1## wherein A is aryl; R.sub.1, R.sub.2 and R.sub.3 are alkyl or heteroalkyl; R.sub.4 is heterocyclic alkyl; and X is S, O or NR.sub.3. This invention also relates to use of these compounds for the treatment of benign prostatic hyperplasia and other diseases where antagonism of the human .alpha..sub.1C receptor is useful. The invention further provides pharmaceutical compositions comprising a therapeutically effective amount of such a compound and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及作为人α1C受体的选择性拮抗剂的二氢嘧啶化合物，其具有以下结构：其中A为芳基; R1，R2和R3是烷基或杂烷基; R4是杂环烷基; X为S，O或NR 3。本发明还涉及这些化合物用于治疗良性前列腺增生症和其它对人α1c受体的拮抗作用有用的其它疾病的用途。本发明还提供包含治疗有效量的这种化合物和药学上可接受的载体的药物组合物。

3. 发明授权

US06268369B1 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines 失效
标题翻译： 5-（杂环烷基）-6-芳基 - 二氢嘧啶
公开(公告)号：US06268369B1
公开(公告)日：2001-07-31
申请号：US08836628
申请日：1997-05-16
申请人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski , Bharat Lagu , Shou Wu Miao
发明人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski , Bharat Lagu , Shou Wu Miao
IPC分类号： C07D4004
CPC分类号： C07D239/30 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/14 , C07D491/04
摘要： This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human &agr;1C receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where antagonism of the &agr;1C receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及下式的二氢嘧啶化合物：它们是人α1C受体的选择性拮抗剂。本发明还涉及这些化合物用于降低眼内压，抑制胆固醇合成，放松下尿路组织，治疗良性前列腺增生，阳ence，心律失常以及用于治疗任何α1C受体拮抗作用的疾病有用本发明还提供了包含治疗有效量的上述化合物和药学上可接受的载体的药物组合物。

4. 发明授权

US06248747B1 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines 失效
标题翻译： 5-（杂环烷基）-6-芳基 - 二氢嘧啶
公开(公告)号：US06248747B1
公开(公告)日：2001-06-19
申请号：US09291553
申请日：1999-04-14
申请人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski
发明人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski
IPC分类号： A61K31505
CPC分类号： C07D239/30 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/14 , C07D491/04
摘要： This invention is directed to the use of dihydropyrimidine compounds, which are selective antagonists for cloned human &agr;1C receptors, for the treatment of benign prostatic hyperplasia and other diseases where antagonism of the human &agr;1C receptor is useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-identified compounds and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及作为克隆的人α1C受体的选择性拮抗剂的二氢嘧啶化合物用于治疗良性前列腺增生症和其它人α1C受体拮抗作用的其它疾病的用途。本发明还提供了包含治疗有效量的上述化合物和药学上可接受的载体的药物组合物。

5. 发明授权

US06608086B2 Dihydropyridines and new uses thereof 失效
标题翻译：二氢吡啶类及其新用途
公开(公告)号：US06608086B2
公开(公告)日：2003-08-19
申请号：US09972801
申请日：2001-10-05
申请人： Charles Gluchowski , John M. Wetzel , George Chiu , Mohammed R. Marzabadi , Wai C. Wong , Dhanapalan Nagarathnam
发明人： Charles Gluchowski , John M. Wetzel , George Chiu , Mohammed R. Marzabadi , Wai C. Wong , Dhanapalan Nagarathnam
IPC分类号： C07D40112
CPC分类号： C07D401/12 , C07D211/90 , C07D401/14 , C07D405/14 , C07D471/04 , C07D471/10 , C07F7/0812
摘要： This invention provides dihydropyridines useful for treatment of prostatic hyperplasia, inhibition of cholesterol synthesis, and/or reduction of intraocular pressure.
摘要翻译：本发明提供了可用于治疗前列腺增生，抑制胆固醇合成和/或降低眼内压的二氢吡啶类。

6. 发明授权

US06211198B1 Dihydropyridines and new uses thereof 失效
标题翻译：二氢吡啶类及其新用途
公开(公告)号：US06211198B1
公开(公告)日：2001-04-03
申请号：US09098699
申请日：1998-06-15
申请人： Charles Gluchowski , John M. Wetzel , George Chiu , Mohammed R. Marzabadi , Wai C. Wong , Dhanapalan Nagarathnam
发明人： Charles Gluchowski , John M. Wetzel , George Chiu , Mohammed R. Marzabadi , Wai C. Wong , Dhanapalan Nagarathnam
IPC分类号： A61K314545
CPC分类号： C07D401/12 , C07D211/90 , C07D401/14 , C07D405/14 , C07D471/04 , C07D471/10 , C07F7/0812
摘要： The invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure: wherein Y is —(CH2)n—, where n is 1, 2, 3, 4 or 5; —(CH2)h—O—(CH2)k—, where h and k are independently the same or different and are 2, 3 or 4; —(CH2)h—CH═CH—(CH2)k—; or —(CH2)h—C≡C—(CH2)k—, where h and k are independently the same or different and are 1, 2, 3 or 4; wherein Z is O, NH, or CH2; wherein R1 is a linear or branched chain alkyl, alkoxyalkyl or arylalkyl group; wherein R2 and R4 are independently the same or different and are H, or a linear or branched chain alkyl group; wherein R3 is H, a linear or branched chain alkyl, alkoxy, alkoxyalkyl or acyl group; and wherein R5 and R6 are independently the same or different and are H, OH, Cl, Br, F, NO2, CN, CF3, or NH2, or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfone, or mono- or dialkylamino group. Other active compounds containing one, two or three rings are also disclosed as well as pharmaceutical compositions prepared therefrom and methods of use in the treatment of BPH, inhibition of cholesterol synthesis, and reduction of intraocular pressure.
摘要翻译：本发明提供一种治疗受试者的良性前列腺增生的方法，其包括向受试者施用治疗有效量的具有以下结构的化合物：其中Y为 - （CH 2）n - ，其中n为1,2,3,4 或5; - （CH 2）h -O-（CH 2）k - ，其中h和k独立地相同或不同，为2,3或4; - （CH 2）h -CH = CH-（CH 2）k - ; 或 - （CH 2）h -C = C-（CH 2）k - ，其中h和k独立地相同或不同，为1,2,3或4; 其中Z是O，NH或CH 2; 其中R1是直链或支链烷基，烷氧基烷基或芳基烷基; 其中R2和R4独立地相同或不同，为H或直链或支链烷基; 其中R3是H，直链或支链烷基，烷氧基，烷氧基烷基或酰基; 并且其中R 5和R 6独立地相同或不同，为H，OH，Cl，Br，F，NO 2，CN，CF 3或NH 2，或直链或支链烷基，烷氧基，烷氧基羰基，酰基，烷基亚砜，烷基砜，或一或二烷基氨基。还公开了含有一个，两个或三个环的其它活性化合物以及由其制备的药物组合物以及用于治疗BPH，抑制胆固醇合成和降低眼内压的方法。

7. 发明授权

US06310076B1 Dihydropyridines and new uses thereof 失效
标题翻译：二氢吡啶类及其新用途
公开(公告)号：US06310076B1
公开(公告)日：2001-10-30
申请号：US09588973
申请日：2000-06-07
申请人： Charles Gluchowski , John M. Wetzel , George Chiu , Mohammed R. Marzabadi , Wai C. Wong , Dhanapalan Nagarathnam
发明人： Charles Gluchowski , John M. Wetzel , George Chiu , Mohammed R. Marzabadi , Wai C. Wong , Dhanapalan Nagarathnam
IPC分类号： C07D40102
CPC分类号： C07D401/12 , C07D211/90 , C07D401/14 , C07D405/14 , C07D471/04 , C07D471/10 , C07F7/0812
摘要： The invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure: wherein Y is —(CH2)n—, where n is 1, 2, 3, 4 or 5; —(CH2)h—O—(CH2)k—, where h and k are independently the same or different and are 2, 3 or 4; —(CH2)h—CH═CH—(CH2)k—; or —(CH2)h—C≡C—(CH2)k—, where h and k are independently the same or different and are 1, 2, 3 or 4; wherein Z is O, NH, or CH2; wherein R1 is a linear or branched chain alkyl, alkoxyalkyl or arylalkyl group; wherein R2 and R4 are independently the same or different and are H, or it linear or branched chain alkyl group; wherein R3 is H, a linear or branched chain alkyl, alkoxy, alkoxyalkyl or acyl group; and wherein R5 and R6 are independently the same or different and are H, OH, Cl, Br, F, NO2, CN, CF3, or NH2, or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfone, or mono- or dialkylamino group. Other active compounds containing one, two or three rings are also disclosed as well as pharmaceutical compositions prepared therefrom and methods of use in the treatment of BPH, inhibition of cholesterol synthesis, and reduction of intraocular pressure.
摘要翻译：本发明提供一种治疗受试者的良性前列腺增生的方法，其包括向受试者施用治疗有效量的具有以下结构的化合物：其中Y为 - （CH 2）n - ，其中n为1,2,3,4 或5; - （CH 2）h -O-（CH 2）k - ，其中h和k独立地相同或不同，为2,3或4; - （CH 2）h -CH = CH-（CH 2）k - ; 或 - （CH 2）h -C = C-（CH 2）k - ，其中h和k独立地相同或不同，为1,2,3或4; 其中Z是O，NH或CH 2; 其中R1是直链或支链烷基，烷氧基烷基或芳基烷基; 其中R2和R4独立地相同或不同，为H，或者是直链或支链烷基; 其中R3是H，直链或支链烷基，烷氧基，烷氧基烷基或酰基; 并且其中R 5和R 6独立地相同或不同，为H，OH，Cl，Br，F，NO 2，CN，CF 3或NH 2，或直链或支链烷基，烷氧基，烷氧基羰基，酰基，烷基亚砜，烷基砜，或一或二烷基氨基。还公开了含有一个，两个或三个环的其它活性化合物以及由其制备的药物组合物和用于治疗BPH，抑制胆固醇合成和降低眼内压的方法。

8. 发明授权

US5767131A Dihydropyridines and new uses thereof 失效
标题翻译：二氢吡啶类及其新用途
公开(公告)号：US5767131A
公开(公告)日：1998-06-16
申请号：US211764
申请日：1996-02-23
申请人： Charles Gluchowski , John M. Wetzel , George Chiu , Mohammed R. Marzabadi , Wai C. Wong , Dhanapalan Nagarathnam
发明人： Charles Gluchowski , John M. Wetzel , George Chiu , Mohammed R. Marzabadi , Wai C. Wong , Dhanapalan Nagarathnam
IPC分类号： C07D211/90 , C07D401/12 , C07D401/14 , C07D405/14 , C07D471/04 , C07D471/10 , C07F7/08 , A01N43/40
CPC分类号： C07D211/90 , C07D401/12 , C07D401/14 , C07D405/14 , C07D471/04 , C07D471/10 , C07F7/0812
摘要： The invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure: ##STR1## wherein Y is --(CH.sub.2).sub.n --, where n is 1, 2, 3, 4 or 5; --(CH.sub.2).sub.h --O--(CH.sub.2).sub.k --, where h and k are independently the same or different and are 2, 3 or 4; --(CH.sub.2).sub.h --CH.dbd.CH--(CH.sub.2).sub.k --; or --(CH.sub.2).sub.h --C.tbd.C--(CH.sub.2).sub.k --, where h and k are independently the same or different and are 1, 2, 3 or 4; wherein Z is O, NH, or CH.sub.2 ; wherein R.sup.1 is a linear or branched chain alkyl, alkoxyalkyl or arylalkyl group; wherein R.sup.2 and R.sup.4 are independently the same or different and are H, or a linear or branched chain alkyl group; wherein R.sup.3 is H, a linear or branched chain alkyl, alkoxy, alkoxyalkyl or acyl group; and wherein R.sup.5 and R.sup.6 are independently the same or different and are H, OH, Cl, Br, F, NO.sub.2, CN, CF.sub.3, or NH.sub.2, or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfone, or mono- or dialkylamino group. Other active compounds containing one, two or three rings are also disclosed as well as pharmaceutical compositions prepared therefrom and methods of use in the treatment of BPH, inhibition of cholesterol synthesis, and reduction of intraocular pressure.
摘要翻译： PCT No.PCT / US94 / 03852 Sec。 371日期1996年2月23日 102（e）日期1996年2月23日PCT 1994年4月5日PCT PCT。公开号WO94 / 22829 1994年10月13日发明内容本发明提供一种治疗受试者的良性前列腺增生的方法，其包括向受试者施用治疗有效量的具有以下结构的化合物：其中Y为 - （CH 2）n - ，其中n 是1，2，3，4或5; - （CH 2）h -O-（CH 2）k - ，其中h和k独立地相同或不同，为2,3或4; - （CH 2）h -CH = CH-（CH 2）k - ; 或 - （CH 2）h -C 3 CF 3 - （CH 2）k - ，其中h和k独立地相同或不同，并且为1,2,3或4; 其中Z是O，NH或CH 2; 其中R1是直链或支链烷基，烷氧基烷基或芳基烷基; 其中R2和R4独立地相同或不同，为H或直链或支链烷基; 其中R3是H，直链或支链烷基，烷氧基，烷氧基烷基或酰基; 并且其中R 5和R 6独立地相同或不同，为H，OH，Cl，Br，F，NO 2，CN，CF 3或NH 2，或直链或支链烷基，烷氧基，烷氧基羰基，酰基，烷基亚砜，烷基砜，或一或二烷基氨基。还公开了含有一个，两个或三个环的其它活性化合物以及由其制备的药物组合物和用于治疗BPH，抑制胆固醇合成和降低眼内压的方法。

9. 发明授权

US5780485A Use of .alpha..sub.1c specific compounds to treat benign prostatic hyperplasia 失效
标题翻译：使用α1c特异性化合物治疗良性前列腺增生
公开(公告)号：US5780485A
公开(公告)日：1998-07-14
申请号：US415681
申请日：1995-04-03
申请人： Charles Gluchowski , Carlos C. Forray , George Chiu , Theresa A. Branchek , John M. Wetzel , Paul R. Hartig
发明人： Charles Gluchowski , Carlos C. Forray , George Chiu , Theresa A. Branchek , John M. Wetzel , Paul R. Hartig
IPC分类号： A61K31/00 , A61K31/135 , A61K31/137 , A61K31/44 , A61K31/4409 , A61K31/4427 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/4545 , A61K31/505 , A61K31/517 , A61K31/55 , A61K45/00 , A61P13/02 , A61P15/00 , A61P43/00 , C07C211/30 , C07C215/50 , C07C215/52 , C07C217/58 , C07C217/60 , C07D211/58 , C07D401/12 , C07D405/12 , C07D495/06
CPC分类号： C07D401/12 , A61K31/00 , A61K31/135 , A61K31/137 , A61K31/44 , A61K31/4409 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/4545 , A61K31/505 , A61K31/517 , A61K31/55 , C07C211/30 , C07C215/50 , C07C215/52 , C07C217/58 , C07C217/60 , C07D211/58 , C07D405/12 , C07D495/06 , C07C2102/08 , C07C2102/10 , C07C2102/12
摘要： A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.
摘要翻译：一种治疗受试者的良性前列腺增生的方法，其包括向受试者施用治疗有效量的结合人α1C肾上腺素能受体的化合物，其结合亲和力比结合亲和力高10倍，化合物与人α1B肾上腺素能受体，人α1B肾上腺素能受体和人组胺H1受体结合，并且结合人α2肾上腺素能受体，其结合亲和力比结合亲和力低10倍该化合物与这种α1C肾上腺素能受体结合。提供符合这些标准的化合物。

10. 发明授权

US5403847A Use of .alpha..sub.1C specific compounds to treat benign prostatic hyperlasia 失效
标题翻译：使用α1C特异性化合物治疗良性前列腺增生
公开(公告)号：US5403847A
公开(公告)日：1995-04-04
申请号：US975867
申请日：1992-11-13
申请人： Charles Gluchowski , Carlos C. Forray , George Chiu , Theresa A. Branchek , John M. Wetzel , Paul R. Hartig
发明人： Charles Gluchowski , Carlos C. Forray , George Chiu , Theresa A. Branchek , John M. Wetzel , Paul R. Hartig
IPC分类号： A61K31/00 , A61K31/135 , A61K31/137 , A61K31/44 , A61K31/4409 , A61K31/4427 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/4545 , A61K31/505 , A61K31/517 , A61K31/55 , A61K45/00 , A61P13/02 , A61P15/00 , A61P43/00 , C07C211/30 , C07C215/50 , C07C215/52 , C07C217/58 , C07C217/60 , C07D211/58 , C07D401/12 , C07D405/12 , C07D495/06
CPC分类号： C07D401/12 , A61K31/00 , A61K31/135 , A61K31/137 , A61K31/44 , A61K31/4409 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/4545 , A61K31/505 , A61K31/517 , A61K31/55 , C07C211/30 , C07C215/50 , C07C215/52 , C07C217/58 , C07C217/60 , C07D211/58 , C07D405/12 , C07D495/06 , C07C2102/08 , C07C2102/10 , C07C2102/12
摘要： A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.
摘要翻译：一种治疗受试者的良性前列腺增生的方法，其包括向受试者施用治疗有效量的结合人α1C肾上腺素能受体的化合物，其结合亲和力比结合亲和力高10倍，化合物与人α1B肾上腺素能受体，人α1B肾上腺素能受体和人组胺H1受体结合，并且结合人α2肾上腺素能受体，其结合亲和力比结合亲和力低10倍该化合物与这种α1C肾上腺素能受体结合。提供符合这些标准的化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式